Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 3

Vaccination: Short- To Long-Term Benefits From Investment


Vaccination: Short- To Long-Term Benefits From Investment

Stuart Carroll et al. J Mark Access Health Policy.


In the context of current economic difficulties across Europe, accurate budgeting and resource allocation have become increasingly important. Vaccination programmes can respond to the needs of governments to budget with confidence. It may be more reliable and accurate to forecast budget and resource allocation for a vaccination programme than for unpredictable seasonal disease peaks of infections such as rotavirus gastroenteritis, influenza, and pneumonia. In addition, prevention through vaccination involves low levels of investment relative to the substantial benefits that may be obtained. In France, total lifelong vaccination costs, per fully compliant individual, ranged from €865 to €3,313, covering 12 to 16 diseases, which is comparable to, or lower than, costs of other preventive measures. In addition, effectively implemented vaccination programmes have the potential to generate substantial savings both in the short and in the long term. For example, vaccination programmes for rotavirus, meningitis C, human papillomavirus, influenza, and pneumonia have all been shown to significantly reduce the disease burden, and thus the associated costs, in the first years following vaccination implementation. These programmes demonstrate the potential for health authorities to obtain early, and often substantial, return on investment.

Keywords: Vaccination; benefits; budget; costs; investment; short-term.


Fig. 1
Fig. 1
Lifelong vaccination costs per fully compliant individual in France (5).
Fig. 2
Fig. 2
Budget impact analysis showing the cumulative mean annual percentage payback predicted for introduction of rotavirus vaccination in England and Wales (7). (a) Immediate vaccine immunity waning after vaccination and (b) delayed vaccine immunity waning after vaccination. Price for a full-course regimen was assumed to be £60.
Fig. 3
Fig. 3
Annual number of meningitis C cases from 1998/1999 to 2009/2010* (10). *Provisional data.

Similar articles

See all similar articles

Cited by 5 articles


    1. OECD Health at a Glance 2013: OECD indicators. Available from: [cited 13 January 2015]
    1. O'Riordan M, Fitzpatrick F. The impact of economic recession on infection prevention and control. J Hosp Infect. 2015;89:340–5. - PubMed
    1. Mao L, Yang Y, Qiu Y, Yang Y. Annual economic impacts of seasonal influenza on US counties: Spatial heterogeneity and patterns. Int J Health Geogr. 2012;11:16. - PMC - PubMed
    1. Zaidman C, Roussel R, Le Garrec MA, Bouvet M, Solard J, Mikou M, et al. Comptes Nationaux de la Santé 2013. [National Health Accounts 2013]. Paris, France: Direction de la recherche des études de l’évaluation et des statistiques (DREES); 2014.
    1. Baron-Papillon F, Cornier M, Remy V, Chriv E. What are the lifelong costs of vaccinating one individual? The French case (Abstrct PIN48) Value Health. 2014;17(7):A672. - PubMed

LinkOut - more resources